Drug
Risankizumab
Risankizumab: highest development phase Phase 3, developed by AbbVie. 6 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- AbbVie
Trials
| Drug | Phase | Indication |
|---|---|---|
| risankizumab NCT02684357 | Phase 3 | Psoriasis |
| risankizumab IV NCT03105128 | Phase 3 | Crohn's Disease |
| Risankizumab NCT06548542 | Phase 2 | Crohn's Disease |
| Risankizumab NCT07007091 | Phase 1 | Healthy Volunteers |
| risankizumab NCT05283694 | Phase 1 | Healthy Volunteers |
| Risankizumab NCT04254783 | Phase 1 | Ulcerative Colitis (UC) |
Latest
No recent events.
Follow Risankizumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.